Medical composition capable of treating hypertension

A composition and a technique for hypertension, applied in the field of medicine, can solve the problems of no calcium ion antagonist, obvious side effects, etc., and achieve the effects of protecting kidney function, improving quality of life, and increasing treatment compliance.

Active Publication Date: 2009-04-29
LUNAN PHARMA GROUP CORPORATION
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Chinese patent application CN03150996.7 (amlodipine, irbesartan compound preparation) discloses a kind of antihypertensive drug compound taking amlodipine and irbesartan as active ingredients, but what it adopts is amlodipine Racemate, obvious side effects
[0007] Chinese patent application CN200510052246.4 (a compound antihypertensive preparation containing telmisartan and calcium ion antagonist and its application) discloses a compound antihypertensive preparation contain

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical composition capable of treating hypertension
  • Medical composition capable of treating hypertension
  • Medical composition capable of treating hypertension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The preparation of embodiment 1 compound tablet

[0021] Levoamlodipine Besylate 5g

[0022] Olmesartan Medoxomil 5g

[0023] Compressible starch 120g

[0024] Cyclodextrin 10g

[0025] Sodium carboxymethyl starch 10g

[0026] Magnesium stearate 0.6g

[0027] 5% PVP in absolute ethanol solution

[0028] Preparation process: first put levamlodipine besylate and cyclodextrin into a mortar, grind and mix evenly, then add carboxymethyl starch sodium, compressible starch and mix evenly, finally add olmesartan and mix evenly, use 5 The absolute ethanol solution of % PVP is used as a binder to granulate, dried at 40°C, granulated, added with magnesium stearate, mixed evenly, and pressed into tablets to obtain the product.

Embodiment 2

[0029] The preparation of embodiment 2 compound powder

[0030] Levoamlodipine Maleate 5g

[0031] Olmesartan Medoxomil 10g

[0032] Microcrystalline Cellulose 8g

[0033] Starch 15g

[0034] Preparation process: pass the prescribed amount of levamlodipine maleate and olmesartan medoxomil through a 100-mesh sieve, starch and microcrystalline cellulose through a 80-mesh sieve, mix evenly, and divide into packages to obtain the product.

Embodiment 3

[0035] The preparation of embodiment 3 compound dropping pills

[0036] Levoamlodipine Besylate 5g

[0037] Olmesartan Medoxomil 20g

[0038] Polyethylene glycol-6000 142g

[0039] Preparation process: pass the prescribed amount of levamlodipine besylate and olmesartan medoxomil through a 100-mesh sieve, mix with polyethylene glycol-6000, heat to a molten state, stir evenly, and use a mechanical device to dissolve the The medicinal material is dropped into cold simethicone oil, cooled and formed, and the simethicone oil is washed away to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a novel medical composition used for treating hypertension and more particularly relate to levamlodipine and olmesartan medoxomil, wherein, the weight ratio of the levamlodipine to the olmesartan medoxomil is 1 to (1-20). The levamlodipine disclosed by the invention comprises salts accepatable in pharmacy, such as benzene sulfonate, maleate and other salts. The medical composition provided by the invention has the advantages of obvious therapeutic effect, convenient usage and low cost.

Description

Technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition for treating hypertension. Background technique [0002] Hypertension is the most common cardiovascular disease and has become a major public health problem worldwide. According to statistics from the national health department, by the end of 2006, the number of hypertensive patients in my country had reached 160 million, and more than 3 million new patients were added every year. [0003] Hypertension is a syndrome with very complicated etiology and pathogenesis. Once diagnosed, it requires life-long medication. At present, domestic and foreign medical circles generally tend to use two antihypertensive drugs with different mechanisms of action in combination. According to the sixth report of the National Committee on the Prevention, Detection, Evaluation, and Treatment of Hypertension, these antihypertensive small-dose fixed compound preparation...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4422A61P9/12A61K31/4178
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap